1、 Global digital health industry
1) Huiyitianxia, an internet medical platform, signed a strategic cooperation agreement with shuomao technology to deeply cultivate the field of chronic respiratory diseases
On August 23, 2021, it was learned that huiyitianxia internet medical platform signed a strategic cooperation agreement with Shanghai shuomao Medical Devices Co., Ltd. the two sides will integrate resources, deeply cultivate the field of chronic respiratory diseases, and provide treatment management solutions for more respiratory doctors and patients. According to the agreement, at the beginning of the cooperation, the electric pressure spray nasal washer of Shuo Mao technology will be combined with the excellent medicines of the Anhui medical world platform as a nursing kit and medical service package for children’s respiratory tract care. Shuo Mao technology, a digital therapy company in the respiratory field, has been committed to using digital tools to help the whole process of respiratory disease diagnosis, treatment and prognosis.
2) Yingsi intelligent and Yihui pharmaceutical have reached a project cooperation to jointly develop small molecule inhibitors for hematological malignancies
On August 20, 2021, it was learned that industrial silicon intelligence, an artificial intelligence drug R & D company, and Yihui pharmaceutical, a biopharmaceutical company, reached a project cooperation. The two sides will jointly develop small molecule inhibitors for hematological malignancies around specific targets. According to the agreement, this cooperation is based on the project of Yihui medicine in the basic R & D stage. The two sides will combine Yihui medicine’s understanding of the biological significance of new targets and its understanding of the current clinical unmet medical needs, with the artificial intelligence drug R & D platform of yingsi intelligence based on deep reinforcement learning technology and massive data training. Make full use of the molecular design means in the frontier field of medical science to improve the efficiency and success rate of key links in drug development, and develop potential best in class small molecule targeted drugs for the signal pathway of specific hematological malignancies.
3) Biotechnology company vyant bio and cyclica announced a cooperation to determine a new method for the treatment of CDKL5 deficiency
On August 19, 2021, the biotechnology company vyant bio, Inc. and cyclica, Inc. announced a non exclusive strategic cooperation to combine vyant bio’s patient derived complex organoid biology with cyclica’s whole proteome artificial intelligence discovery platform to determine a new method for the treatment of CDKL5 deficiency. By combining the technologies of the two companies, CDD based drug discovery aims to identify, validate and promote new goals and new and existing compounds to simplify and reduce risk.
4) Johnson & Johnson and optellum, an artificial intelligence company, have reached a cooperation to identify early lung cancer cases
On August 18, 2021, Johnson & Johnson announced that its department focusing on developing tools for the prevention and treatment of lung cancer was cooperating with optellum, a clinical decision support startup, whose recent early detection tool was approved by the regulatory authorities. Optellum’s clinical decision support software tool was approved by FDA in March. The software is designed for use by pulmonary doctors and radiologists. It analyzes CT scans and assigns predictive scores to nodules that may represent early lung cancer.
5) Babyscripts, a maternal and infant health care platform, cooperates with privia health for remote pregnancy care
On August 18, 2021, it was learned that privia health, a national doctor authorized company cooperating with the medical group, health plan and health system, cooperated with babyscripts, a maternal and infant health care platform, to provide its suppliers with babyscripts platform, so that privia women’s health doctors can provide the most advanced remote care to pregnant women and postpartum patients in the country. This collaboration aims to provide privia health’s doctors with a virtual nursing experience and remote patient monitoring for their pregnant patients.
1）Google announced the dissolution of its health department, Google health
On August 21, 2021, it was learned that Google would dissolve its health department Google Health, and David Feinberg, head of the Department, would leave on September 1. Google Health’s projects and teams will be distributed to different departments of Google. Founded in 2018, Google heath has always been an important product department of Google. As of March this year, the Department has about 700 employees engaged in research, imaging, clinical tools and health sensors. At the same time, Cerner, one of the largest medical information companies in the United States, announced that David Feinberg would join the company as CEO and president.
2) Yitu technology plans to go public in Hong Kong, raising about HK $31.2 billion
It was learned on August 19, 2021 that according to foreign media news, Yitu technology, a mainland artificial intelligence company, plans to go public in Hong Kong as soon as this year, raising about US $4 billion. According to the source, after a long review, the regulatory authorities rejected its listing application last month, eventually making the company decide to list in Hong Kong. However, it is said that the board of directors has not completely ruled out the possibility of listing on the Shanghai Science and innovation board.
2、 Global digital health capital
1.Investment and financing
1) Covera health, a clinical analysis service provider, completed round C financing of US $25 million to promote the development of medical quality analysis platform
On August 23, 2021, covera health, a clinical analysis service provider, announced that it had completed round C financing of US $25 million. This round of financing was led by insight partners and followed by existing investors including equity group investments. The financing will enable the company not only to meet the growing demand for insight into its medical quality, but also to greatly expand its innovative product suite to support doctors and payers in their efforts to improve patient outcomes.
2) Zhiyuan huitu completed nearly 100 million yuan of round B financing and enabled human eye health management with AI technology
On August 23, 2021, Beijing Zhiyuan huitu Technology Co., Ltd., the global leader in the field of eye health artificial intelligence, announced the completion of nearly 100 million yuan of round B financing. This round of financing is led by Qiming venture capital and followed by the old shareholder Danlu capital. The financing funds will be used for team expansion, product R & D, clinical project registration and market development, so as to further consolidate the company’s medical science and technology strength. Vistel was founded in 2016 by former Intel executive sun Yuhui and researcher Ding Dayong. It is committed to providing solutions based on artificial intelligence and intelligent ophthalmic hardware in disease screening and diagnosis through cooperation with excellent ophthalmic medical teams.
3) Ruixin medical completed hundreds of millions of yuan of round C financing, aiming to build the world’s first accurate and intelligent heart brain integrated diagnosis and treatment platform
On August 23, 2021, Shenzhen Ruixin Intelligent Medical Technology Co., Ltd. (Ruixin medical) announced the completion of hundreds of millions of yuan of round C financing. It is reported that the financing is led by SDIC, the old shareholders continue to follow, and Huaxing capital acts as the exclusive financial adviser. The financing will be used to accelerate the market landing of the product matrix, promote the scale of service scenarios, expand the technical team, attract more cutting-edge talents to participate in innovation and R & D, and comprehensively and deeply promote the landing of Ruixin medical’s “professional, fine, characteristic and novel” intelligent diagnosis and treatment platform. Ruixin medical is an innovative medical enterprise that takes ct-ffr (noninvasive blood flow reserve fraction) as the starting point of product R & D and develops intelligent and accurate diagnosis and treatment of cardiovascular and cerebrovascular AI.
4) Mixlab, a digital pet pharmacy platform, announced the completion of a round of financing of US $20 million, led by Sonoma brands
Recently, mixlab, a digital pet pharmacy platform, announced the completion of round a financing of US $20 million. This round of financing is led by Sonoma brands, followed by global founders capital, Monogram capital, Lakehouse ventures and brand foundry. So far, the total financing of mixlab has reached US $30 million. Mixlab’s digital pharmacy platform covers door-to-door delivery of branded drugs, generic drugs, compound drugs and over-the-counter drugs, reducing the inventory pressure of clinics and pharmacies. Veterinarians can quickly prescribe prescriptions through the mixlab platform and track the medication progress and treatment compliance, so as to simplify the daily medication workflow.
5) Bosch medical has completed a round of financing of nearly 100 million yuan and will enter the track of intelligent surgery
It was learned on August 20, 2021 that Guangzhou Boshi Medical Technology Co., Ltd., an overall solution provider of AI enabled precision medicine, has completed round a financing. The amount of this financing is nearly 100 million yuan, led by the old shareholder Guangzhou xienochentu Equity Investment Co., Ltd. and the strategic investor Philips (China) Investment Co., Ltd., followed by Hangzhou gaolue Investment Management Co., Ltd. and maibai capital as the financial adviser of this round of financing. The current round of financing funds will be used to accelerate the commercialization of the company’s intelligent radiotherapy products, plan new product R & D for intelligent surgery, and further improve the national sales network.
6) Modern animal, a pet medical service platform, announced a round B financing of US $40 million
On August 20, 2021, modern animal, a pet medical service platform, recently received $40 million in round B financing, led by founders fund. Modern animal is an American pet medical service platform. Pet owners can contact veterinarians through online app at any time, including text communication, voice and video call services. They can also make an appointment online app. After arriving at the hospital, they can enjoy treatment without queuing.
7) Kuiwei technology has completed round B financing of RMB 100 million for team building, technology iteration and further expansion of industry application
On August 18, 2021, it was learned that the privacy computing head enterprise “Kuiwei technology” received a billion yuan round B financing. This round of financing was supported by many well-known venture funds including Zhiyuan Internet, Lianyu investment and Hainan range. The original shareholders represented by angel round investor Li Gang capital and round a investor Qiming venture capital continued to support this round of financing. This round of financing funds will be used for team building, technology iteration and further expansion of industry applications. It will also promote the accelerated expansion of privacy computing technology of Weiwei technology in many fields and serve the development of digital economy. Weiwei technology is a specialized service provider of privacy computing. The company is based on Weixin ® Privacy computing platform is the core, including a series of products such as medical big data privacy computing platform and government big data privacy computing platform. At present, it has taken the lead in landing more than 10 cross domain and multi center privacy computing projects, providing a new infrastructure guarantee for data sharing and analysis.